Literature DB >> 21821673

Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges.

Géraldine Sicot1, Geneviève Gourdon, Mário Gomes-Pereira.   

Abstract

Expanded, non-coding RNAs can exhibit a deleterious gain-of-function causing human disease through abnormal interactions with RNA-binding proteins. Myotonic dystrophy (DM), the prototypical example of an RNA-dominant disorder, is mediated by trinucleotide repeat-containing transcripts that deregulate alternative splicing. Spliceopathy has therefore been a major focus of DM research. However, changes in gene expression, protein translation and micro-RNA metabolism may also contribute to disease pathology. The exciting finding of bidirectional transcription and non-conventional RNA translation of trinucleotide repeat sequences points to a new scenario, in which DM is not mediated by one single expanded RNA transcript, but involves multiple pathogenic elements and pathways. The study of the growing number of human diseases associated with toxic repeat-containing transcripts provides important insight into the understanding of the complex pathways of RNA toxicity. This review describes some of the recent advances in the understanding of the molecular mechanisms behind DM and other RNA-dominant disorders.

Entities:  

Mesh:

Year:  2011        PMID: 21821673     DOI: 10.1093/hmg/ddr343

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  44 in total

1.  The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.

Authors:  Auinash Kalsotra; Ravi K Singh; Priyatansh Gurha; Amanda J Ward; Chad J Creighton; Thomas A Cooper
Journal:  Cell Rep       Date:  2014-01-09       Impact factor: 9.423

2.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

Authors:  Linda L Bachinski; Keith A Baggerly; Valerie L Neubauer; Tamara J Nixon; Olayinka Raheem; Mario Sirito; Anna K Unruh; Jiexin Zhang; Lalitha Nagarajan; Lubov T Timchenko; Guillaume Bassez; Bruno Eymard; Josep Gamez; Tetsuo Ashizawa; Jerry R Mendell; Bjarne Udd; Ralf Krahe
Journal:  Neuromuscul Disord       Date:  2013-11-15       Impact factor: 4.296

3.  Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Authors:  Siham Ait Benichou; Dominic Jauvin; Thiéry De Serres-Bérard; Marion Pierre; Karen K Ling; C Frank Bennett; Frank Rigo; Genevieve Gourdon; Mohamed Chahine; Jack Puymirat
Journal:  Gene Ther       Date:  2022-01-25       Impact factor: 5.250

Review 4.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

5.  Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.

Authors:  Konstantinos Charizanis; Kuang-Yung Lee; Ranjan Batra; Marianne Goodwin; Chaolin Zhang; Yuan Yuan; Lily Shiue; Melissa Cline; Marina M Scotti; Guangbin Xia; Ashok Kumar; Tetsuo Ashizawa; H Brent Clark; Takashi Kimura; Masanori P Takahashi; Harutoshi Fujimura; Kenji Jinnai; Hiroo Yoshikawa; Mário Gomes-Pereira; Geneviève Gourdon; Noriaki Sakai; Seiji Nishino; Thomas C Foster; Manuel Ares; Robert B Darnell; Maurice S Swanson
Journal:  Neuron       Date:  2012-08-09       Impact factor: 17.173

6.  Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.

Authors:  Ginny R Morriss; Kimal Rajapakshe; Shixia Huang; Cristian Coarfa; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

7.  Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case series.

Authors:  Devin Gattey; Angela Y Zhu; Anna Stagner; Mark A Terry; Albert S Jun
Journal:  Cornea       Date:  2014-01       Impact factor: 2.651

Review 8.  Regulatory Potential of Competing Endogenous RNAs in Myotonic Dystrophies.

Authors:  Edyta Koscianska; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  Smaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.

Authors:  Maria de Haro; Ismael Al-Ramahi; Karlie R Jones; Jerrah K Holth; Lubov T Timchenko; Juan Botas
Journal:  PLoS Genet       Date:  2013-04-18       Impact factor: 5.917

10.  Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model.

Authors:  Beatriz Llamusi; Ariadna Bargiela; Juan M Fernandez-Costa; Amparo Garcia-Lopez; Raffaella Klima; Fabian Feiguin; Ruben Artero
Journal:  Dis Model Mech       Date:  2012-11-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.